Which funds bought or sold NVS in Q3 2026?
Novartis Ag. 2 funds bought, 5 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$222M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Citadel+$184M
- Fisher Investments+$177M
- GQG−$300M
- Holocene−$80M
- Northern Trust−$37M
- Farallon−$15M
- Dodge & Cox−$3M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (2)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Citadel Quant & multi-strategy | Added+403% | +$184M | $230M |
| Fisher Investments Asset manager | Added+8% | +$177M | $2.4B |
Sold (5)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| GQG Growth / crossover | Trimmed-97.8% | −$300M | $7M |
| Holocene Hedge fund | Trimmed-54.1% | −$80M | $68M |
| Northern Trust Bank & broker | Trimmed-9.3% | −$37M | $361M |
| Farallon Hedge fund | Trimmed-29.8% | −$15M | $36M |
| Dodge & Cox Value investor | Trimmed-3.2% | −$3M | $105M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.